Surmodics, Inc. (NASDAQ:SRDX – Get Free Report) saw a significant decline in short interest in August. As of August 15th, there was short interest totalling 462,000 shares, a decline of 36.9% from the July 31st total of 732,100 shares. Currently, 3.4% of the company’s stock are sold short. Based on an average daily volume of 466,400 shares, the days-to-cover ratio is currently 1.0 days.
Analyst Ratings Changes
Several brokerages recently issued reports on SRDX. Needham & Company LLC reiterated a “hold” rating on shares of Surmodics in a research note on Monday, August 5th. Barrington Research reissued a “market perform” rating on shares of Surmodics in a research report on Thursday, May 30th. Lake Street Capital reaffirmed a “hold” rating and set a $43.00 price objective on shares of Surmodics in a research report on Wednesday, May 29th. Sidoti reissued a “neutral” rating and issued a $43.00 target price on shares of Surmodics in a report on Wednesday, May 29th. Finally, StockNews.com started coverage on Surmodics in a research note on Tuesday. They issued a “hold” rating on the stock. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, Surmodics currently has a consensus rating of “Hold” and a consensus target price of $50.00.
Get Our Latest Analysis on Surmodics
Institutional Inflows and Outflows
Surmodics Stock Down 0.1 %
Shares of Surmodics stock opened at $39.53 on Wednesday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.22 and a current ratio of 3.98. The stock has a market capitalization of $563.70 million, a PE ratio of 41.61 and a beta of 1.18. Surmodics has a 52-week low of $25.17 and a 52-week high of $42.44. The company has a 50-day simple moving average of $41.31 and a two-hundred day simple moving average of $35.35.
About Surmodics
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
Read More
- Five stocks we like better than Surmodics
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Snowflake’s Risk/Reward Profile Is Too Good To Miss
- Why Are Stock Sectors Important to Successful Investing?
- Akamai: AI Tailwinds Drive Edge Computing and Security Growth
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- DoorDash Stock Sprints Higher on EPS Beat and Raised Guidance
Receive News & Ratings for Surmodics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics and related companies with MarketBeat.com's FREE daily email newsletter.